Today's Rundown Biotech boom powers analysts to $4M-a-year salaries: WSJ Women’s health firm KaNDy raises $32M for menopause study Reality check for Hong Kong biotech IPOs as Ascletis slips Xenon’s epilepsy drug clears phase 1b, setting stage for trial in patients Targeting Alzheimer’s with a soluble toll-like receptor Indian government committee calls for Johnson & Johnson to pay patients for recalled hip implants Featured Story | | | Wednesday, August 29, 2018 The biotech boom is having a big effect on the pay packets of equity analysts, according to The Wall Street Journal. Driven by a desire to show they understand biotech, banks are reportedly paying analysts up to $4 million a year, several times more than the typical salary in other industries. |
|
|
Top Stories Wednesday, August 29, 2018 KaNDy Therapeutics now has the finances it needs to start a phase 2b trial of its nonhormonal therapy for menopausal symptoms. Wednesday, August 29, 2018 Ascletis Pharma, the first biotech to list in Hong Kong under its exchange’s new rules, has fallen 44% in its first month of trade, a wake-up call for other biotech companies looking to follow in its footsteps. Wednesday, August 29, 2018 A phase 1b trial has linked Xenon’s epilepsy candidate XEN1101 to statistically significant declines in measures of corticospinal and cortical excitability. The data tee Xenon up to move the Kv7 potassium channel opener into a phase 2 trial in adult focal seizures by the end of the year. Wednesday, August 29, 2018 Scientists at the University of Florida found that soluble versions of toll-like receptors—proteins believed to play a key role in the neuro-inflammatory response seen in Alzheimer's—could hold promise in reversing amyloid plaques. Wednesday, August 29, 2018 A panel convened by the Indian drug and medical device regulator has recommended Johnson & Johnson compensate each Indian patient that had to undergo revision surgeries or suffered adverse reactions to its metal-on-metal hip implants recalled in August 2010. | This week's sponsor is ExL Events. | | Let’s talk about success: Technology transfer with a CMO partner | ExL's 5th Technology Transfer for Biologics Conference
Gain expert insights on how to create successful partnerships with CMOs and the partnership management skills needed to maintain biologics quality at every step of process transfer.
View the full agenda —Save 15% with code FIERCE |
Resources Sponsored by: AWS and Tableau Inova is using the capabilities of Tableau on AWS to identify biomarkers for personalized treatment intended to improve health outcomes for children. Sponsored by: AWS and Reltio Reltio and IQVIA provide holistic data management solutions for traditional pharma, emerging biotech, and consumer health companies, on AWS. Presented by: AWS and Druva Life Sciences organizations are embracing cloud-based Master Data Management (MDM) to modernize the organization of critical data. Sponsored by: Health Strategies Group The window of market exclusivity continues to narrow dramatically in the global marketplace. Given this demanding environment, your global market access team faces increasing urgency to get the value proposition right at the time of launch. Sponsored by: Patheon, part of Thermo Fisher Scientific “Faster and better” has become the mantra for biopharmaceutical companies as they face intense pressure to get therapies to market faster. Quickly proving efficacy in first-in-human (FIH) trials is a make-or-break milestone for these cash-strapped companies whose hopes hinge upon one or two molecules. Read how CDMOs are responding to this pressure. Sponsored by: PharmaCord When was the last time your patient support program perfectly aligned with the patient journey, solving all the critical gaps in positioning your brand for success? Follow the 3-D approach to your solution design, and you will achieve a better outcome for your patients. Sponsored by: WCG Selecting the right sites is the most crucial decision you’ll make in your next clinical trial, and the single most important factor to consider in selecting a site is whether or not it can meet its enrollment goals. Sponsored by: Veeva Industry Research: See new results from one of the industry's largest, global clinical operations surveys. Sponsored by: Veeva Ready to modernize your RIM environment? Secure buy-in with these tips. Sponsored by: Catalent Develop a basic understanding of principles and concepts of bioavailability of oral drugs. Drug Approval, Manufacturing Quality & Regulation 2018 | Online RESI HealthTech Week September 5-7, 2018 | Boston, MA 2018 Latin America Healthcare Compliance Certification Program September 24-27, 2018 | Sao Paulo, Brazil Drug Development Immersion September 26-27, 2018 | West Windsor, NJ FierceBiotech 3rd Drug Development Forum October 1–3, 2018 | Hilton Boston Logan Airport Hotel | Boston, MA Compliance Certification Program at Seton Hall Law October 8-11, 2018 | Newark, NJ BioImmersion: Biotech for the Non-Scientist October 16-18, 2018 | Chicago, IL 2018 BIO Investor Forum October 17-18, 2018 | Westin St. Francis, San Francisco, CA FierceBiotech Executive Summit: London October 30, 2018 | Royal Society of Medicine Drug Development Boot Camp® 2018 – Register Now! November 14-15, 2018 | Boston, MA | Register now and start your pre-Boot Camp preparation Field Service Amsterdam November 27-28, 2018 | NH Collection Amsterdam Grand Hotel Krasnapolsky | 